Navigation Links
ISTA Pharmaceuticals Announces Positive Preliminary Results from,Ecabet Sodium Phase IIb Study

a predetermined endpoint in this study, 14 percent of patients in the treatment group reported increases in the quantity of tears produced, as compared to only 1.8 percent in the placebo group. We are continuing our analyses of both of our Phase II clinical studies to identify the signs and symptoms to evaluate in Phase III testing. Upon completion of the analyses, we will request a meeting with the Food and Drug Administration to discuss its recommended clinical path in order to bring this novel treatment to patients suffering from dry eye syndrome. At this time, we anticipate beginning Phase III studies in 2008."

A total of 112 patients were assigned randomly to receive either ecabet sodium or placebo four times a day for 90 days. There were four primary efficacy endpoints: two objective signs (blink rate and corneal staining) and two subjective symptoms (the patient's most bothersome symptom and the patient's response to the Ocular Surface Disease Index (OSDI)). Patients were evaluated in a controlled adverse environment ("dry eye chamber") twice during the study, once on Day 1 and once on Day 91. The objective signs were measured pre- and post-exposure to the dry eye chamber on Day 91. The subjective symptoms were measured following exposure to the dry eye chamber on both Day 1 and Day 91. To date, the FDA has considered improvement, as measured in Phase III studies, in one sign and one symptom to be acceptable for approval of a prescription dry eye product.

ISTA will host a conference call with a simultaneous webcast tomorrow, Friday, June 1, 2007, at 11:00 AM Eastern Time to discuss today's announcement regarding the ecabet sodium Phase IIb study preliminary results and other recent product and commercial developments. To access the live conference call, U.S. and Canadian participants may dial 866-356-4281; international participants may dial 617-597-5395. The access code for the live call is 93323302. To access the 24-hour audio replay, U.S. an
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/27/2014)... Aug. 27, 2014 Decision Resources Group finds ... Memphis health system and hospital ... integration, with rivals Methodist Le Bonheur Healthcare and Baptist ... to coordinate patient care. In addition, a national contract ... most health plan enrollment in the Memphis ...
(Date:8/27/2014)... By now, if you haven,t heard about the ALS Ice ... awareness campaign has brought this devastating disease to the forefront ... Million (and counting) for ALS. Every day, more and more ... as well. One such company, Acorn Stairlifts Inc., ... works with ALS sufferers and helps to provide solutions for ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Heart Valve Repair and Replacement ... About Heart Valve Repair and Replacement ... which control the flow of blood during the ... diseases such as valvular stenosis, valvular insufficiency or ...
Breaking Medicine Technology:Memphis-area Health Systems Turn Attention to Clinical Integration 2Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
(Date:8/27/2014)... 27, 2014 BESLER Consulting , ... services for hospitals, is pleased to announce that it ... of America’s Fastest-Growing Companies. The list represents the most ... independent entrepreneurs. , "It's been an exciting year ... included in this year's Inc. 5000 list,” said Jonathan ...
(Date:8/27/2014)... designed to help regulate the blood,s iron supply shows promise ... to results from the first human study of ... , the Journal of the American Society of Hematology ... blood cells are in short supply or do not function ... get enough oxygen, since there are fewer red blood cells ...
(Date:8/27/2014)... State University,s Center for Leadership in Disability (CLD) ... Maternal and Child Health Bureau of the Health ... the Autism Plan for Georgia, aimed at improving ... disorder. , In preparing for this project, CLD ... key stakeholders from across Georgia. The resulting plan ...
(Date:8/27/2014)... Cash House 's contributions to Horizons ... upkeep of the shelter including new initiatives and a wide ... the lives of each youth who walk through their door. ... for youth ages 16-25. Not only does Horizons operate as ... for the youth who come through their doors. Horizons has ...
(Date:8/27/2014)... Houston, TX (PRWEB) August 27, 2014 ... The reality is that depression has a mortality ... those with bi-polar disorder is slightly less, though it's ... of roughly 7%. In order to properly treat ... schizophrenia, and bi-polar, medication must be taken as directed. ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Drug represents first potential treatment for common anemia 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3Health News:MedicationDiscountCard.com now Makes Brintellix and Mental Illness Medications More Affordable with Discount Cards 2
... Kingdom recently instituted guidelines banning physicians, white coats and ... of bacteria within hospitals due to the belief that ... new study published today in the Journal of ... there is no difference in contamination of long- and ...
... - In an international Phase III randomized study, ... rapamycin (mTOR), has shown to dramatically improve progression-free ... (pNET), according to researchers from The University of ... findings were published in the latest New England ...
... Maureen Salamon HealthDay Reporter , WEDNESDAY, Feb. ... more than doubled the progression-free survival time for patients ... two new studies. In separate phase 3 trials ... sunitinib extended the survival of participants with advanced pancreatic ...
... Feb. 9 (HealthDay News) -- About one in 10 ... after. Though typically harmless, some may need treatment because ... "There are several different types of birthmarks, so it ... considering any possible treatments," dermatologist Dr. Sheila Fallon Friedlander, ...
... the National Institutes of Health envisions scientists being able ... gaining new insights into multi-gene disorders in the next ... drug targets and the development of practical treatments for ... plan from the National Human Genome Research Institute (NHGRI). ...
... PARK, Md. -- Under our feet and ubiquitous, lowly soil ... change and population growth. But in the January-February issue of ... team of scientists say soil is an essential piece of ... it. Strategies for doing so include refocusing and boosting research, ...
Cached Medicine News:Health News:Long- and short-sleeved physician workwear receive same amount of bacterial and MRSA contamination 2Health News:Everolimus improves progression-free survival for patients with rare pancreatic cancer 2Health News:Everolimus improves progression-free survival for patients with rare pancreatic cancer 3Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 2Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 3Health News:Not All Birthmarks Harmless, Expert Says 2Health News:NHGRI charts course for the next phase of genomics research 2Health News:NHGRI charts course for the next phase of genomics research 3Health News:NHGRI charts course for the next phase of genomics research 4Health News:Soil science: Healing our planet's ills from the ground up 2
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Medicine Products: